These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 14602459)

  • 21. P95 HER2 fragments and breast cancer outcome.
    Tural D; Akar E; Mutlu H; Kilickap S
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1089-96. PubMed ID: 24968823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression profiling of breast tumors based on human epidermal growth factor receptor 2 status defines migration-related genes.
    Cuadros M; Cano C; López FJ; López-Castro R; Concha A
    Pathobiology; 2013; 80(1):32-40. PubMed ID: 22832278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
    Ram TG; Schelling ME; Hosick HL
    Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced expression of the UROC28 gene in human breast cancer: relationship to ERBB2 gene expression.
    Kamagata C; Tsuji N; Kondoh K; Sasaki M; Kobayashi D; Yagihashi A; Watanabe N
    Anticancer Res; 2002; 22(6C):4087-91. PubMed ID: 12553037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer.
    De Maria R; Olivero M; Iussich S; Nakaichi M; Murata T; Biolatti B; Di Renzo MF
    Cancer Res; 2005 Feb; 65(3):907-12. PubMed ID: 15705889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of HER2-induced endothelial cell retraction.
    Carter WB; Niu G; Ward MD; Small G; Hahn JE; Muffly BJ
    Ann Surg Oncol; 2007 Oct; 14(10):2971-8. PubMed ID: 17593333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.
    Ross JS; Fletcher JA
    Semin Cancer Biol; 1999 Apr; 9(2):125-38. PubMed ID: 10202134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.
    Vanden Bempt I; Van Loo P; Drijkoningen M; Neven P; Smeets A; Christiaens MR; Paridaens R; De Wolf-Peeters C
    J Clin Oncol; 2008 Oct; 26(30):4869-74. PubMed ID: 18794552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
    Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
    Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anthracyclines and the tailoring of treatment for early breast cancer.
    Piccart-Gebhart MJ
    N Engl J Med; 2006 May; 354(20):2177-9. PubMed ID: 16707755
    [No Abstract]   [Full Text] [Related]  

  • 32. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.
    Tokunaga E; Oki E; Kimura Y; Yamanaka T; Egashira A; Nishida K; Koga T; Morita M; Kakeji Y; Maehara Y
    Breast Cancer Res Treat; 2007 Mar; 101(3):249-57. PubMed ID: 17006756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER2 regulatory control of angiopoietin-2 in breast cancer.
    Carter WB; Ward MD
    Surgery; 2000 Aug; 128(2):153-8. PubMed ID: 10922985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
    Ethier SP; Kokeny KE; Ridings JW; Dilts CA
    Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiplex ligation-dependent probe amplification for HER2 testing in breast cancer.
    Farshid G
    Expert Rev Mol Diagn; 2011 Nov; 11(8):767-9. PubMed ID: 22022937
    [No Abstract]   [Full Text] [Related]  

  • 36. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
    Witton CJ; Reeves JR; Going JJ; Cooke TG; Bartlett JM
    J Pathol; 2003 Jul; 200(3):290-7. PubMed ID: 12845624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Observer prediction of HER2 amplification in HercepTest 2+ breast cancers as a potential audit instrument.
    Going JJ
    Histopathology; 2011 Aug; 59(2):333-5. PubMed ID: 21884213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2/neu expression in cancer: the pathologist as diagnostician or prophet?
    Foster CS; Gosden CM; Ke Y
    Hum Pathol; 2003 Jul; 34(7):635-8. PubMed ID: 12874757
    [No Abstract]   [Full Text] [Related]  

  • 39. Antitumor efficacy of piperine in the treatment of human HER2-overexpressing breast cancer cells.
    Do MT; Kim HG; Choi JH; Khanal T; Park BH; Tran TP; Jeong TC; Jeong HG
    Food Chem; 2013 Dec; 141(3):2591-9. PubMed ID: 23870999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.
    Brunelli M; Manfrin E; Martignoni G; Miller K; Remo A; Reghellin D; Bersani S; Gobbo S; Eccher A; Chilosi M; Bonetti F
    Am J Clin Pathol; 2009 May; 131(5):678-82. PubMed ID: 19369627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.